Source disclosure: February 06, 2026
OncoTherapy Science,Inc. [4564.T]
TOKYO, Feb 18 (Pulse News Wire) – Oncotherapy Science,Inc. (4564.T) reported consolidated results for Q3 FY2026 (ending March 2026).
1% YoY).
48 billion with an equity ratio of 83.3%.
For the next fiscal year, the company forecasts 0%).
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms • Original filing💬 Help us improve translation quality
Notice any errors in this article? Let us know with one click.